Eli Lilly’s triple‑agonist retatrutide delivered unprecedented weight loss in a Phase 3 study—averaging roughly 28.7% at 68 weeks—while also improving knee osteoarthritis pain. The high efficacy readout positions retatrutide as a potential best‑in‑class obesity candidate and has spurred broad market attention and investor reactions. However, trial data also showed elevated discontinuation and adverse‑event rates, including reports of intolerability in some patients who experienced rapid weight loss. Clinicians and payers will now weigh the magnitude of efficacy against tolerability and safety signals as regulatory filings and longer‑term data emerge. Competitors and investors are recalibrating expectations for the obesity market based on Lilly’s results.